Lifeloc Technologies Annual Shareholders Meeting June 1, 2022



Committed to safer roads and workplaces worldwide

1

Welcome Shareholders

- Agenda
- Shareholder Votes per Proxy Statement
- State of the Company

Lifeloc Technologies

Safe Harbor Agreement

This presentation contains forward-looking statements which reflect management's expectations regarding Lifeloc's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Where possible words such as "plans," "expects" or "does not expect," "budget," "forecasts," "anticipates" or "does not anticipate," "believes," "intends" and similar expressions or statements that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved, have been used to identify these forward-looking statements. Although the forward-looking statements contained in this presentation reflect management's current assumptions based upon information currently available to management and based upon that which management believes to be reasonable assumptions, Lifeloc cannot be certain that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause Lifeloc's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: international and domestic operations, customer demand, regulatory matters credit and customer concentration; competition; rapid technological change; product liability claims; intellectual property; use of non-GAAP financial measures; significant shareholder; supply arrangements; and dependence upon key management personnel and executives. For more details, please see the "Risk Factors" section of our SEC filing.

Although Lifeloc has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, as noted above, you should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this presentation and, except as required by law, Lifeloc assumes no obligation to update or revise them to reflect new events or circumstances.

3

Lifeloc Today

- Installed base in over 65 countries.
- Global penetration in both workplace testing and law enforcement
- · Core Business is generally cash flow positive
- \$7.05 million sales, 2021
- Equivalent of 36 full time employees
- Big growth opportunity is real time drug testing

Δ

Post Pandemic

COVID-19 pandemic dominated company agenda


- Benefit from PPP, both rounds
- Sales recovering from both pent-up demand and new products
- Workforce partially remote, as possible
- Supply chain challenges push many component lead times to 12 months
- · Broad price increases

5

2021 Income Statement

Income Statement	2021	2020
Revenue	\$ 7,054.430	\$ 6,356,702
Gross Profit	\$ 3,060,096	\$ 2,180,546
Gross Margin	43.4%	34.3%
R&D	\$ 1,213,482	\$ 1,007,297
Sales	\$ 1,003,983	\$ 1,074,249
General and Admin	\$ 1,111,544	\$ 1,254,503
PPP Benefit	\$ 936,444	\$ 0
Pretax Income	\$ 619,660	\$(1,197,338)
Net Income	\$ 675,967	\$ (921,930)

6





New Platform LX9 and LT7



Sold in:

Australia Bolivia

Columbia Denmark

Finland India

Indonesia Malaysia

Mexico New Zealand

Poland Tonga

United States Uruguay

With additional approvals

expected

9

R.A.D.A.R.® Status

- R.A.D.A.R. 200 model has updated communication, improved mechanical reliability and GPS accuracy
- Customer trials indicate market demands include upgrades to biometrics
- Lifeloc is exploring options to upgrade without diverting any resources from SpinDx



10

Rapid Drug Testing

- The rapid drug testing market remains our best opportunity for the growth that we seek.
- The drug testing needs are enormous and growing.
- Growing marijuana legalization is normalizing abuse.
 Legalization only increases the need rapid drug detection.

11

SpinDx Development SpinDx design complete, rendered image is shown First prototype of this design has been built

SpinDx Development

- SpinDx methodology:
 - Most sensitive (5ng/ml), demonstrated in saliva
 - Quantitative
 - Discriminating
 - Portable
 - Rapid, current analysis time under 30 minutes, with improvements expected
- Leverage the Lifeloc capability to design and manufacture rugged portable testers
- Lifeloc has existing channel to both Law Enforcement and Workplace markets



13

SpinDx Development Status

- · Lifeloc designed prototype has been built
- Hardware being optimized
- Purchase commitments made for components for initial small build quantity
- R&D team committed with SpinDx commercialization as primary objective
- Incentives in place to accelerate commercial introduction



SpinDx Business Model

- SpinDx reader is the basis of a broad platform of rapid drug tests
- Disks for different tests different tests will be an ongoing development effort
- There will be a steady stream of disks with tests for broader panels and accuracy
- Readers will be able to analyze future disk tests with firmware upgrades
- Disks and collection kits are higher value consumables than mouthpieces



15

SpinDx Next Steps

- · Human, real user samples being collected
- First product release will be a SpinDx reader with liquid (saliva) marijuana analysis disk
- Breath analysis disk will follow as soon as possible



Lifeloc Growth Summary

New products (LX9, LT7, and EasyCal G2) and sales initiatives will drive immediate growth.

Cash flow form these will be used to fund the ultimate growth target of real time drug testing without major shareholder dilution.

17

Thank you Lifeloc shareholders for your continued support